The effects of a CXCR1/CXCR2 antagonist on neutrophil migration in mild atopic asthmatic subjects - Todd, Candice M.; Salter, Brittany M.; Murphy, Desmond M.; Watson, Richard M.; Howie, Karen J.; Milot, Joanne; Sadeh, Jonathan; Boulet, Louis-Philippe; O'Byrne, Paul M.; Gauvreau, Gail M. (Pulmonary pharmacology & therapeutics, 2016)
Keywords: Adult; Asthma; Asthma - drug therapy; Asthma - physiopathology; Benzamides - adverse effects; Benzamides - pharmacology; Bone marrow; Cell Movement - drug effects; Cross-Over Studies; CXCR2; Cyclobutanes - adverse effects; Cyclobutanes - pharmacology; Double-Blind Method; Female; Humans; Induced sputum; Male; Medical Education; Neutrophil migration; Neutrophils - drug effects; Neutrophils - metabolism; Peripheral blood; Pulmonary/Respiratory; Receptors, Interleukin-8A - antagonists & inhibitors; Receptors, Interleukin-8B - antagonists & inhibitors; Sputum - metabolism; Young Adult; fMLP; IS; BM; BAL; LPS; Asthma; PB; CXCL12; SAE; CXCR2; Peripheral blood; Neutrophil migration; Bone marrow; FEV1; HBSS; Induced sputum; SCH 527123; Bronchoalveolar Lavage; Hanks Balanced Salt Solution; Lipopolysaccharide; formyl-methionyl-leucyl-phenylalanine; 2-hydroxy- N, N-dimethyl-3-{2-[[( R)-1-(5-methyl-furan-2-yl)-propyl]amino]-3,4-dioxo-cyclobut-1-enylamino}-benzamide; Stromal derived factor 1; FEV 1; Forced Expiratory Volume in 1 s; CXC Chemokine Receptor 2; Serious Adverse Events